advertising
-
1.
World Health Organization: WHO Global Strategy for Containment of Antimicrobial Resistance, World Health Organization, Geneva, Switzerland, 2001. WHO/CDS/CSR/DRS/2001.2.
-
2.
Rice LB: Progress and challenges in implementing the research on ESKAPE pathogens. Infect Control Hosp Epidemiol 31: S7, 2010.
-
3.
Kollef KE, Schramm GE, Wills AR, et al: Predictors of 30-day mortality and hospital costs in patients with ventilator associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest 134: 281, 2008.
-
4.
Kollef MH: Appropriate empiric antimicrobial therapy of nosocomial pneumonia: the role of the carbapenems. Respir Care 49: 1530, 2004.
-
5.
DiazGranados CA, Zimmer SM, Klein M, et al: Comparsion of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal blood stream infections: a meta analysis. Clin Infect Dis 41: 327, 2005.
-
6.
Schwaber MJ, Navon-Venezia S, Kaye KS, et al: Clinical and economic impact of bacteremia with extended spectrum β-lactamase producing Enterobacteriaceae. Antimicrob Agents Chemother 250: 1257, 2006.
-
7.
Fishman N: Antimicrobial stewardship. Am J Med 119: S53, 2006.
-
8.
Drew RH: Antimicrobial stewardship programs: how to start and steer a successful program. J Manag Care Pharm 15: S18, 2009.
-
9.
Dellit TH, Owens RC, McGowan JE, et al: Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for development of an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 44: 159, 2007.
-
10.
Cannella C: Importance and impact of antimicrobial stewardship. Hosp Pharm 45: S1, 2010.
-
11.
File TM: Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia. Clin Infect Dis 39: S159. 2004.
-
12.
Polk RE, Fishman NO: “Antimicrobial Stewardship,” in Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, 7th Ed, edited by G Mandell, JE Bennett, R Dolin, Churchill Livingstone, Philadelphia, 2010.
-
13.
Smith RG: Vancomycin: an overview for the podiatric physician. JAPMA 94: 389, 2004.
-
14.
Dryden M, Johnson AP, Ashiru-Oredope D, et al: Using antibiotics responsibly: right drug, right time, right dose, right duration. J Antimicrob Chemother 66: 2441, 2011.
-
15.
Drew RH, White R, MacDougall C, et al: Insights from Society of Infectious Diseases Pharmacists on antimicrobial stewardship guidelines from the Infectious Diseases Society of America and the Society for Health Epidemiology of America. Pharmacotherapy 29: 593, 2009.
-
16.
Cristian H, Nascu PC, Gornic EG, et al: Severe, extensive, soft tissue infections. TMJ 53: 272, 2003.
-
17.
Stulberg DL, Penrod MA, Blatny RA: Common bacteria skin infections. Am Fam Physician 66: 119, 2002.
-
18.
Burn JI, Curwen MP, Huntsman RG, et al: Atrial of penicillin V: response of penicillin-resistant staphylococcal infections to penicillin. BMJ 2: 193, 1957.
-
19.
Lee MC, Rios AM Aten MF, et al: Management and outcome of children with skin and soft tissue abscess caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 23: 123, 2004.
-
20.
Moran GJ Amii RN, Abrahamian FM, et al: Methicillin-resistant Staphylococcus aureus community-acquired skin infections. Emerg Infect Dis 11: 928, 2005.
-
21.
Wong CH, Khin LW, Heng KS, et al: The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med 32: 1535, 2004.
-
22.
Stevens DL, Bisno AL, Chambers HF, et al: Practice guidelines for diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 41: 1373, 2005.
-
23.
Hepburn MJ, Dooley DP, Skidmore PJ, et al: Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulites. Arch Intern Med 164: 1669, 2004.
-
24.
Spellberg B, Lipsky BA: Systemic antibiotic therapy for chronic osteomyelitis in adults. Clin Infect Dis 54: 393, 2012.
-
25.
Fraimow HS: Systemic antimicrobial therapy in osteomyelitis. Semin Plast Surg 23: 90, 2009.
-
26.
Tice AD, Hoaglund PA, Shoultz DA: Risk factors and treatment outcomes in osteomyelitis. J Antimicrob Chemother 51: 1261, 2003.
-
27.
Lew DP, Waldvogel FA: Osteomyelitis. Lancet 364: 369, 2004.
-
28.
Lazzarini L, De Lalla F, Mader JT: Long bone osteomyelitis. Curr Infect Dis Rep 4: 439, 2002.
-
29.
Liu C, Bayer A, Cosgrove SE, et al: Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52: 1, 2011.
-
30.
Sia IG, Berbari EF: Infection and musculoskeletal conditions: ostemyelitis. Best Pract Res Clin Rheumatol 20: 1065, 2006.
-
31.
Shuford JA, Steckelberg JM: Role of oral antimicrobial therapy in the management of osteomyelitis. Curr Opin Infect Dis 16: 515, 1988.
-
32.
Mader JT, Landon GC, Calhoun J: Antimicrobial treatment of osteomyelitis. Clin Orthop Relat Res 295: 87, 1993.
-
33.
Lipsky BA, Berendt AR, Deery HG, et al: Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 39: 885, 2004.
-
34.
Roine I, Faingezicht I, Arguedas A, et al: Serial serum c-reactive protein to monitor recovery from acute hematogenous osteomyelitis in children. Pediatr Infec Dis J 14: 40, 1995.
-
35.
Becker KL, Snider R, Nylen ES: Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 36: 941, 2008.
-
36.
Muller B, Becker KL, Schachinger H, et al: Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 28: 977, 2000.
-
37.
Hayashi Y, Paterson DL: Strategies for reduction in duration of antibiotic in hospitalized patients. Clin Infect Dis 52: 1232, 2011.
-
38.
National Committee for Clinical Laboratory Standards: 2002 Analysis and Presentation of Cumulative Susceptibility Test Data; Approved Guideline, National Committee for Clinical Laboratory Standards, Wayne, PA, 2002. NCCLS document M39-A.
-
39.
Hindler JF, Stelling J: Analysis and presentation of cumulative antibiograms: a new consensus guideline from the Clinical and Laboratory Standards Institute. Clin Infect Dis 44: 867, 2007.
-
40.
Centers for Disease Control and Prevention: Get Smart for Healthcare. Available at: http://www.cdc.gov/drugresistance/healthcare. Accessed November 14, 2013.
-
41.
Clinical and Laboratory Standards Institute: Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data; Approved Guidelines, 2nd Ed, Clinical and Laboratory Standards Institute, Wayne, PA, 2006. CLSI document M39-A2.
Antibiotic Stewardship
The Lower-Extremity Physician's Prescription for Effectively Treating Infection
Search for other papers by Robert G. Smith in
Current site
Google Scholar
PubMed
Search for other papers by Warren S. Joseph in
Current site
Google Scholar
PubMed
The discovery of antibiotic drugs was one of the most significant medical achievements of the 20th century. The improper use of antibiotic drugs to prevent and treat infections has resulted in the emergence of resistance. Antimicrobic stewardship programs are becoming a mainstay in the fight against multidrug-resistant organisms. Individual clinicians should be encouraged to adopt the principles of antibiotic stewardship when treating lower-extremity infections in their scope of practice. First, a review of the available literature outlining the concept and practice of antibiotic stewardship is offered. Second, a discussion describing how to adopt and apply these principles to the individual clinician's practice as it applies to lower-extremity infections is offered. Finally, specific antimicrobial pharmacologic spectra and antibiogram information are offered.
advertising
